1 week Ago By ABMN Staff
Norges Bank purchased a new position in shares of Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN – Free Report ) in the 4th quarter, HoldingsChannel.com reports.
The institutional investor purchased 169,000 shares of the company’s stock, valued at approximately $2,141,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DAWN. NEOS Investment Management LLC grew its stake in Day One Biopharmaceuticals by 8.
7% in the fourth quarter. NEOS Investment Management LLC now owns 85,761 shares of the company’s stock valued at $1,087,000 after purchasing an additional 6,878 shares in the last quarter. BIT Capital GmbH lifted its holdings in shares of Day One Biopharmaceuticals by 41.
8% during the 4th quarter. BIT Capital GmbH now owns 171,714 shares of the company’s stock valued at $2,176,000 after buying an additional 50,626 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at approximately $150,000.
Teacher Retirement System of Texas increased its holdings in Day One Biopharmaceuticals by 20.9% in the fourth quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock worth $226,000 after buying an additional 3,086 shares during the last quarter.
Finally, Intech Investment Management LLC raised its position in Day One Biopharmaceuticals by 50.1% during the fourth quarter. Intech Investment Management LLC now owns 34,888 shares of the company’s stock valued at $442,000 after acquiring an additional 11,652 shares in the last quarter.
87.95% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth Several analysts have commented on DAWN shares.
HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush reiterated an “outperform” rating and issued a $32.
00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th.
The Goldman Sachs Group decreased their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, March 25th.
Finally, Bank of America cut their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th.
Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $32.29.
Insider Activity In related news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.
08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40.
This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink .
Also, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.
96, for a total value of $52,265.20. Following the sale, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.
48. The trade was a 1.70 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Over the last ninety days, insiders have sold 21,064 shares of company stock worth $251,925. Company insiders own 8.
40% of the company’s stock. Day One Biopharmaceuticals Stock Up 5.3 % DAWN opened at $7.
12 on Friday. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.
41 and a 12-month high of $18.07. The stock’s 50 day moving average price is $9.
33 and its two-hundred day moving average price is $12.05. The firm has a market capitalization of $721.
65 million, a P/E ratio of -6.91 and a beta of -1.24.
Day One Biopharmaceuticals ( NASDAQ:DAWN – Get Free Report ) last released its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.
35) by ($0.34). The company had revenue of $29.
21 million for the quarter, compared to analyst estimates of $27.11 million. As a group, analysts anticipate that Day One Biopharmaceuticals, Inc.
will post -0.72 earnings per share for the current year. Day One Biopharmaceuticals Profile ( Free Report ) Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.
Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. Read More Want to see what other hedge funds are holding DAWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Day One Biopharmaceuticals, Inc.
( NASDAQ:DAWN – Free Report ). Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
